Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Princess Margaret Cancer Center University of Toronto Toronto, Canada Wednesday, August 21, 13 Princess Margaret Cancer Center Wednesday, August 21, 13 University Health Network (Teaching Hospitals Part of University of Toronto) • Princess Margaret Cancer Center • Toronto General Hospital/TGRI • Toronto Western Hospital/TWRI • Toronto Rehab/TRI Wednesday, August 21, 13 PMCC: Nestled In the Vibrant University Avenue Community •Samuel Lunenfeld Research Institute-Mt. Sinai •Hospital for Sick Children •University of Toronto •Ontario Institute for Cancer Research Wednesday, August 21, 13 CONFIDENTIAL Wednesday, August 21, 13 PMCC Research: A Snapshot • 63 Scientists and Senior Scientists 12 Affiliate and Assistant Scientists 165 Clinician-Investigators • $122,557,000 external funding (2010/11) • 815 publications (2010/11) • 370 clinical trials involving 7,000 patients - Home to NIH Phase I and II consortia - Site for NIH Cancer Immunotherapy Network Wednesday, August 21, 13 Comparative Publication Analysis % Cited % H ighly Cited Papers % in H igh-‐Impact Journals 120% 100% 80% 60% 40% 20% 0% Dana Farber Johns Hopkins Mayo Clinic MD Anderson Sloan Kettering U Washington PMH/UHN Higher-‐Impact Journals Represen'ng <2% of all journals, journals with a Cita'on-‐to-‐publica'ons ra'o of >5 are considered higher-‐impact Journals Cita6on Bibliographic acknowledgement of the contribu'on of one work to another. The number of 'mes a work is referenced by others indicates its impact on a body of knowledge. Rates vary considerably by subject area. Highly-‐cited paper Papers with a cita'on count placing it amongst the top 10% of papers published in the year and subject-‐area (as per ESI). High-‐impact groups commonly have 25%-‐30% of papers achieving this standing Wednesday, August 21, 13 Full Spectrum of Research ! Basic Wednesday, August 21, 13 ! Translational ! Clinical Organized To Foster Full Spectrum of Research PMCC Research PMCC Clinical Dir: Dr. Benjamin Neel Dir: Dr. Mary Gospodarowicz Research Executive Council Division Heads Research Council on Oncology Wednesday, August 21, 13 Strength In Key Research Areas • Cancer Biology & Therapeutics - Stem cells (Dick, Neel, Iscove, Khokha, Keller) - Cell and Matrix Biology - Signal transduction (Muthuswamy, Khokha, Stambolic)* (Neel, Muthuswamy, Rottapel, Stambolic, Ikura, Teidelman) - Tumor hypoxia (Wouters, Hill, Muthuswamy, Bristow) - Structural biology - Radiobiology (Ikura, Arrowsmith, Prive) (Bristow, Wouters, Hill, Koch) - DNA damage and repair Wednesday, August 21, 13 (Bristow, Koch) Strength In Key Research Areas • Cancer Genomics & Biomarkers - Epigenetis (Lupien, Arrowsmith, De Carvalho) - Proteomics (Moran, Kisslinger, Raught) - Clinical Genomics (Roehl, Pugh)* - Computational Biology Wednesday, August 21, 13 (Jurisca, Hoffman)* Strength In Key Research Areas • Immunology & Immuno Therapy - Mak, Ohashi, Paige, Hirano, Naoto • Imaging & Image guided therapeutics - Jaffray, Zheng, Wilson, Vitkin Wednesday, August 21, 13 Translation To Clinic at PMCC Drug Development Program (Malcolm Moore) •NIH Phase I Consortium (Lillian Siu) •NIH Phase II Consortium (Amit Oza) •Supported by AMPL, Pharmacology Lab CCRU •Supports all phases of clinical trials •Biostatistics •Cancer Registries •Other Clinical Trials Support 18,000 patients/year; 12,000 with new cancers Wednesday, August 21, 13 PMCC: A Long History of Accomplishments • Hematopoietic stem cells • T cell receptor • Leukemia (and Cancer) stem cells • Mammographic Density and Breast Cancer • Local Radiation for Breast Cancer • Treatment standards for many other cancers Wednesday, August 21, 13 PMCC Research: Nationally and Internationally Recognized • Lasker Award (Till, McCullough) • Gairdner Award (Till, McCullough, Mak) • G.H. Clowes Award (Dick) • Nobel Award (Dick, Mak, Hill, Ikura) • Dameshek Prize (Dick) • E. Donnall Thomas Prize (Dick) • NCIC Golden Jubilee Awards (Till, McCullough, Dick) Wednesday, August 21, 13 Our Strategic Plan:Personalized Cancer Medicine •Detect ! •Diagnose •Target ! •Support Wednesday, August 21, 13 Our Strategic Plan: Personalized Cancer Medicine • Detect ! > Molecular Imaging** > Biomarkers > Advanced Biobanking • Diagnose >Precision genomics** >Advanced Molecular Pathology** • Target ! >Better cancer models** >Better targets: high throughput screens/Epigenetics**/CSCs* >Immune-therapy** • Support >Psychosocial Oncology/Survivorship Wednesday, August 21, 13 The PMCC 5-Year Vision of Personalized Cancer Medicine • Complete genomic characterization of every tumor • Pharmacogenomic characterization of each patient (differences in drug response) Personalized “targeted (new) therapies” (CSC, epigenetics, signal transduction, computational biology) • • • (Re-) activating the patient's immune system against the tumor (Immune Therapy) Individualizing imaging of tumors (molecular imaging) • Personalized surgical and radiation therapy (imaged-guided therapies) • Personalized management of symptoms of disease and therapy-induced complications (psychosocial oncology, survivorship) Wednesday, August 21, 13